Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 10%
Buy 20%
Hold 70%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst Inc. has demonstrated a strong upward trajectory in earnings power over the past seven years, characterized by increasing EBITDA and a growing client base, alongside a reduction in headcount, which suggests improved operational efficiency. Positive sentiment from healthcare executives indicates that demand for Health Catalyst's modules is rising, as they report better-than-expected patient volumes and an increase in purchases. Furthermore, as the acute care market begins to recover from previous inflationary pressures and staffing challenges, the anticipated increase in demand for Health Catalyst's solutions and services positions the company favorably for continued revenue growth and improved margins.

Bears say

Health Catalyst Inc has experienced a slowdown in total revenue growth, raising concerns about future revenue and EBITDA growth as the total addressable market appears highly penetrated. Despite a modest revenue and EBITDA beat in the third quarter and maintained guidance, the company faces potential sequential revenue declines and a downward revision in the 2026 revenue outlook, suggesting ongoing financial challenges. Additionally, pressures on margins, declines in net dollar-based retention, and a challenging hospital buying environment amplify the negative outlook for Health Catalyst’s stock.

HCAT has been analyzed by 10 analysts, with a consensus rating of Hold. 10% of analysts recommend a Strong Buy, 20% recommend Buy, 70% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 10 analysts, HCAT has a Hold consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.